2023 World Conference on Lung Cancer (Posters)-EP13.04. Preliminary Results of a Prospective Trial of Hypofractionated Radiotherapy Versus Hyperfractionated Radiotherapy for Limited-stage SCLC

EP13.04. Preliminary Results of a Prospective Trial of Hypofractionated Radiotherapy Versus Hyperfractionated Radiotherapy for Limited-stage SCLC - PDF(Abstract)

Back to course

Pdf Summary

This document provides preliminary results of a prospective trial comparing the efficacy of hypofractionated radiotherapy to hyperfractionated radiotherapy for the treatment of limited-stage small cell lung cancer (SCLC). The study aimed to evaluate the clinical outcomes of both treatment approaches, combined with concurrent chemotherapy.<br /><br />The trial included 74 patients who were randomized to receive either hypofractionated or hyperfractionated thoracic radiotherapy. The hypofractionated arm received 45Gy in 15 fractions once a day, while the hyperfractionated arm received 45Gy in 30 fractions twice a day. Chemotherapy consisted of either EP (etoposide and cisplatin) or EC (etoposide and carboplatin) for 4-6 cycles, administered concurrently with radiotherapy. Patients who responded well to the treatment received prophylactic cranial irradiation (PCI) at a specified dosage.<br /><br />The study evaluated progression-free survival (PFS), overall survival (OS), and short-term efficacy as primary outcomes. The analysis found no significant differences in 1- and 2-year OS rates and 1- and 2-year PFS rates between the hypofractionated and hyperfractionated arms. However, there was a trend towards improved clinical outcomes in the hypofractionated arm.<br /><br />Regarding adverse events, the incidence of grade 3 and above hematologic toxicity and radiation pneumonitis showed no significant differences between the two arms. However, the incidence of grade 3 radiation esophagitis was significantly lower in the hypofractionated arm. The incidence of grade 1 and 2 radiation pneumonitis was also lower in the hypofractionated arm.<br /><br />In conclusion, the preliminary results suggest that hypofractionated radiotherapy may lead to improved prognosis for patients with limited-stage SCLC. Further studies with a larger sample size and extended follow-up are needed to confirm these findings.

Asset Subtitle

Xiao Hu

Meta Tag

Speaker Xiao Hu

Topic SCLC & Neuroendocrine Tumors: LS-SCLC

Keywords

prospective trial

hypofractionated radiotherapy

hyperfractionated radiotherapy

limited-stage small cell lung cancer

SCLC

clinical outcomes

concurrent chemotherapy

randomized

progression-free survival

overall survival